Hydroquinone 5-

Akt Nanog Oct4 Sox2 c-Myc cancer stem cell lung cancer mTOR renieramycin M

Journal

Pharmaceuticals (Basel, Switzerland)
ISSN: 1424-8247
Titre abrégé: Pharmaceuticals (Basel)
Pays: Switzerland
ID NLM: 101238453

Informations de publication

Date de publication:
30 Oct 2021
Historique:
received: 22 09 2021
revised: 25 10 2021
accepted: 27 10 2021
entrez: 27 11 2021
pubmed: 28 11 2021
medline: 28 11 2021
Statut: epublish

Résumé

Cancer stem cells (CSCs) are distinct cancer populations with tumorigenic and self-renewal abilities. CSCs are drivers of cancer initiation, progression, therapeutic failure, and disease recurrence. Thereby, novel compounds targeting CSCs offer a promising way to control cancer. In this study, the hydroquinone 5-

Identifiants

pubmed: 34832894
pii: ph14111112
doi: 10.3390/ph14111112
pmc: PMC8621304
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : research grant for talented mid-career researchers (TMRs) from the National Research Council of Thailand (NRCT), Thailand .
ID : STF6400601

Références

Mar Drugs. 2015 Jan 07;13(1):202-21
pubmed: 25574736
Am J Cancer Res. 2015 Apr 15;5(5):1602-9
pubmed: 26175931
Oncogene. 2010 Mar 4;29(9):1249-59
pubmed: 20101214
Front Cell Dev Biol. 2017 Feb 03;5:7
pubmed: 28217689
J Comput Chem. 2010 Jan 30;31(2):455-61
pubmed: 19499576
Cold Spring Harb Perspect Med. 2014 Mar 01;4(3):
pubmed: 24591536
J Cheminform. 2011 Oct 07;3:33
pubmed: 21982300
PLoS One. 2010 Sep 23;5(9):e12913
pubmed: 20886116
Stem Cells. 2016 Aug;34(8):2040-51
pubmed: 27144349
J Comput Chem. 2004 Jul 15;25(9):1157-74
pubmed: 15116359
Signal Transduct Target Ther. 2018 Feb 23;3:5
pubmed: 29527331
Cell Stem Cell. 2012 Apr 6;10(4):440-54
pubmed: 22482508
Mar Drugs. 2019 Feb 11;17(2):
pubmed: 30754694
Cell. 2006 Aug 25;126(4):663-76
pubmed: 16904174
Oncogene. 2009 Aug 6;28(31):2796-805
pubmed: 19483725
Mar Drugs. 2019 Aug 23;17(9):
pubmed: 31443597
Int J Biochem Cell Biol. 2006 Feb;38(2):157-63
pubmed: 16213777
Mol Med Rep. 2017 Apr;15(4):1869-1876
pubmed: 28259993
Int J Oncol. 2017 Apr;50(4):1341-1351
pubmed: 28259926
J Comput Chem. 2009 Dec;30(16):2785-91
pubmed: 19399780
J Chem Theory Comput. 2015 Aug 11;11(8):3696-713
pubmed: 26574453
Mar Drugs. 2020 Aug 10;18(8):
pubmed: 32785022
Trends Cell Biol. 2005 Mar;15(3):128-37
pubmed: 15752976
J Nat Prod. 2003 Nov;66(11):1441-6
pubmed: 14640515
J Biol Chem. 2004 Sep 10;279(37):38903-11
pubmed: 15247222
Cancer Res. 2010 Dec 1;70(23):9937-48
pubmed: 21118965
J Nat Prod. 2017 May 26;80(5):1541-1547
pubmed: 28459574
Anticancer Res. 2020 Feb;40(2):609-618
pubmed: 32014901
Adv Exp Med Biol. 2016;890:57-74
pubmed: 26703799
BMC Res Notes. 2012 Jul 23;5:367
pubmed: 22824207
Expert Opin Drug Discov. 2015 May;10(5):449-61
pubmed: 25835573
Int J Mol Sci. 2019 May 11;20(9):
pubmed: 31083525
Cancer Med. 2015 Dec;4(12):1853-62
pubmed: 26471868
Int J Biochem Cell Biol. 2012 Dec;44(12):2144-51
pubmed: 22981632
J Chem Theory Comput. 2012 Sep 11;8(9):3314-21
pubmed: 26605738
Theranostics. 2020 Jul 9;10(19):8721-8743
pubmed: 32754274
Anticancer Res. 2017 Nov;37(11):6259-6267
pubmed: 29061809
PLoS One. 2013;8(2):e56691
pubmed: 23424671
Oncotarget. 2015 Sep 22;6(28):26494-507
pubmed: 26317998
Biomed Res Int. 2014;2014:126586
pubmed: 24527434
Pathol Res Pract. 2018 Jul;214(7):1000-1007
pubmed: 29773426
Int J Cancer. 2012 Apr 1;130(7):1671-81
pubmed: 21544815
Nature. 2001 Nov 1;414(6859):105-11
pubmed: 11689955
Chem Rev. 2002 May;102(5):1669-730
pubmed: 11996547
J Cheminform. 2012 Aug 13;4(1):17
pubmed: 22889332
Chin J Cancer. 2013 Sep;32(9):483-7
pubmed: 23419197
Cancer Lett. 2013 Jan 1;328(1):144-51
pubmed: 22935675
Mol Cell. 2012 Nov 30;48(4):627-40
pubmed: 23041284
Mar Drugs. 2014 Jan 14;12(1):255-78
pubmed: 24424355
Int J Mol Sci. 2020 Jul 11;21(14):
pubmed: 32664542
Front Cell Dev Biol. 2020 Feb 18;8:79
pubmed: 32133359
Anticancer Res. 2017 Feb;37(2):615-621
pubmed: 28179308
J Chem Phys. 2007 Jan 7;126(1):014101
pubmed: 17212484
Int J Oncol. 2016 Mar;48(3):869-85
pubmed: 26698230
Redox Biol. 2020 Oct;37:101701
pubmed: 32863234
Signal Transduct Target Ther. 2020 Feb 7;5(1):8
pubmed: 32296030

Auteurs

Nattamon Hongwiangchan (N)

Cell-Based Drug and Health Products Development Research Unit, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok 10330, Thailand.
Pharmaceutical Sciences and Technology Graduate Program, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok 10330, Thailand.

Nicharat Sriratanasak (N)

Cell-Based Drug and Health Products Development Research Unit, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok 10330, Thailand.
Department of Pharmacology and Physiology, Faculty of Pharmaceutical Sciences, Chulalongkorn Univesity, Bangkok 10330, Thailand.

Duangdao Wichadakul (D)

Department of Computer Engineering, Faculty of Engineering, Chulalongkorn University, Bangkok 10330, Thailand.

Nithikoon Aksorn (N)

Department of Clinical Pathology, Faculty of Medicine Vajira Hospital, Navamindradhiraj University, Bangkok 10300, Thailand.

Supakarn Chamni (S)

Department of Pharmacognosy and Pharmaceutical Botany, Chulalongkorn University, Bangkok 10330, Thailand.
Natural Products and Nanoparticles Research Unit (NP2), Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok 10330, Thailand.

Pithi Chanvorachote (P)

Cell-Based Drug and Health Products Development Research Unit, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok 10330, Thailand.
Department of Pharmacology and Physiology, Faculty of Pharmaceutical Sciences, Chulalongkorn Univesity, Bangkok 10330, Thailand.

Classifications MeSH